(secondQuint)Fimasartan (BR-A-657) Multiple Oral Dose in Healthy Subjects.

 BR-A-657 120, 360, or placebo were administered once daily for 7days to 16 healthy male subjects.

 Pharmacokinetic and Pharmacodynamic(PK/PD) parameters were monitored at pre-specified times from each subjects.

 PK parameters: Area Under the Curve(AUC), Cmax, half-life, etc.

 PD parameters: Aldosterone, Plasma renin activity, Angiotensin I, Angiotensin II Adverse events are reported.

.

 Fimasartan (BR-A-657) Multiple Oral Dose in Healthy Subjects@highlight

The objective of this study is to determine the safety and tolerability and to determine the Pharmacokinetic and Pharmacodynamic(PK/PD) of ascending multiple oral dose of BR-A-657 in healthy male subjects.

